ITeos Therapeutics Inc (NASDAQ: ITOS) open the trading on Wednesday, with a bit cautious approach as it glided -1.56% to $8.85, before settling in for the price of $8.99 at the close. Taking a more long-term approach, ITOS posted a 52-week range of $8.70-$18.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -23.53%. Meanwhile, its Annual Earning per share during the time was -40.62%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -13.92%. This publicly-traded company’s shares outstanding now amounts to $35.84 million, simultaneously with a float of $28.08 million. The organization now has a market capitalization sitting at $323.20 million. At the time of writing, stock’s 50-day Moving Average stood at $12.87, while the 200-day Moving Average is $13.25.
ITeos Therapeutics Inc (ITOS) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. ITeos Therapeutics Inc’s current insider ownership accounts for 23.11%, in contrast to 83.91% institutional ownership.
ITeos Therapeutics Inc (ITOS) Earnings and Revenue Records
ITeos Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -13.92% and is forecasted to reach -5.36 in the upcoming year.
ITeos Therapeutics Inc (NASDAQ: ITOS) Trading Performance Indicators
Let’s observe the current performance indicators for ITeos Therapeutics Inc (ITOS). It’s Quick Ratio in the last reported quarter now stands at 18.08. The Stock has managed to achieve an average true range (ATR) of 0.60. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 9.23.
In the same vein, ITOS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.00, a figure that is expected to reach -1.17 in the next quarter, and analysts are predicting that it will be -5.36 at the market close of one year from today.
Technical Analysis of ITeos Therapeutics Inc (ITOS)
[ITeos Therapeutics Inc, ITOS] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 18.47% While, its Average True Range was 0.52.
Raw Stochastic average of ITeos Therapeutics Inc (ITOS) in the period of the previous 100 days is set at 2.32%, which indicates a major fall in contrast to 13.84% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 53.24% that was lower than 71.46% volatility it exhibited in the past 100-days period.
